WO2009128692A1 - Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas - Google Patents

Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas Download PDF

Info

Publication number
WO2009128692A1
WO2009128692A1 PCT/MX2008/000051 MX2008000051W WO2009128692A1 WO 2009128692 A1 WO2009128692 A1 WO 2009128692A1 MX 2008000051 W MX2008000051 W MX 2008000051W WO 2009128692 A1 WO2009128692 A1 WO 2009128692A1
Authority
WO
WIPO (PCT)
Prior art keywords
progesterone
method described
injectable
concentrations
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MX2008/000051
Other languages
English (en)
Spanish (es)
French (fr)
Inventor
John Claude Savoir Vilboeuf
Juan Angeles Uribe
María Teresa DE JESÚS FRANCISCO DOCE
Aurelio DE GYVES LÓPEZ LENA
Juan Ramón MARTÍNEZ DE LEÓN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Posi Visionary Solutions LLP
Original Assignee
Posi Visionary Solutions LLP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0822165-0A priority Critical patent/BRPI0822165A2/pt
Priority to CA2721509A priority patent/CA2721509A1/en
Priority to CN2008801294325A priority patent/CN102056611A/zh
Priority to PCT/MX2008/000051 priority patent/WO2009128692A1/es
Priority to EP08741598A priority patent/EP2272519A4/en
Priority to JP2011504940A priority patent/JP2011516606A/ja
Application filed by Posi Visionary Solutions LLP filed Critical Posi Visionary Solutions LLP
Priority to US12/937,779 priority patent/US20110104289A1/en
Publication of WO2009128692A1 publication Critical patent/WO2009128692A1/es
Priority to IL208723A priority patent/IL208723A0/en
Priority to MX2010011296A priority patent/MX2010011296A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/MX2008/000051 2008-04-14 2008-04-14 Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas Ceased WO2009128692A1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2721509A CA2721509A1 (en) 2008-04-14 2008-04-14 Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
CN2008801294325A CN102056611A (zh) 2008-04-14 2008-04-14 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物
PCT/MX2008/000051 WO2009128692A1 (es) 2008-04-14 2008-04-14 Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas
EP08741598A EP2272519A4 (en) 2008-04-14 2008-04-14 METHOD AND PHARMACEUTICAL COMPOSITION FOR ACHIEVING THE PLASMA PROGESTERONE MIRRORS NECESSARY FOR VARIOUS THERAPEUTIC INDICATIONS
JP2011504940A JP2011516606A (ja) 2008-04-14 2008-04-14 様々な治療指標に必要な血漿プロゲステロン濃度を得るための方法および医薬組成物
BRPI0822165-0A BRPI0822165A2 (pt) 2008-04-14 2008-04-14 Método para manter concentrações plasmáticas sustentadas de progesterona em seres humanos, composição farmacêutica, uso de uma composição farmecêutica e suspensão aquosa injetável.
US12/937,779 US20110104289A1 (en) 2008-04-14 2008-04-14 Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
IL208723A IL208723A0 (en) 2008-04-14 2010-10-14 Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
MX2010011296A MX2010011296A (es) 2008-04-14 2010-10-14 Metodo y composicion farmaceutica para lograr niveles plasmaticos de progesterona requeridos para diferentes indicaciones terapeuticas.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2008/000051 WO2009128692A1 (es) 2008-04-14 2008-04-14 Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas

Publications (1)

Publication Number Publication Date
WO2009128692A1 true WO2009128692A1 (es) 2009-10-22

Family

ID=41199287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2008/000051 Ceased WO2009128692A1 (es) 2008-04-14 2008-04-14 Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas

Country Status (8)

Country Link
US (1) US20110104289A1 (enExample)
EP (1) EP2272519A4 (enExample)
JP (1) JP2011516606A (enExample)
CN (1) CN102056611A (enExample)
BR (1) BRPI0822165A2 (enExample)
CA (1) CA2721509A1 (enExample)
IL (1) IL208723A0 (enExample)
WO (1) WO2009128692A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2019086410A1 (en) * 2017-10-30 2019-05-09 Carmentix Pte. Ltd. Biomarkers of preterm birth

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019484A1 (fr) * 1990-06-14 1991-12-26 Aplicaciones Farmaceuticas, S.A. De C.V. Composition pharmaceutique injectable
US5643604A (en) 1990-06-14 1997-07-01 Aplicaciones Farmaceuticas S.A. De C.V. Parenteral dosage form
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0474117A (ja) * 1990-07-16 1992-03-09 Kokuritsu Eisei Shikenjo 新規なマイクロスフェア
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
ATE454885T1 (de) * 2003-06-13 2010-01-15 Skendi Finance Ltd Mikrosphären von estradiol und cholesterol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019484A1 (fr) * 1990-06-14 1991-12-26 Aplicaciones Farmaceuticas, S.A. De C.V. Composition pharmaceutique injectable
US5360616A (en) 1990-06-14 1994-11-01 Applicaciones Farmaceuticas S.A. De C.V. Injectable pharmaceutical composition
US5643604A (en) 1990-06-14 1997-07-01 Aplicaciones Farmaceuticas S.A. De C.V. Parenteral dosage form
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MENOCAL, G. ET AL.: "Progesterona in microesferas para the tratamiento in infertilidad.", ACTA MÉDICA GRUPO ANGELES., vol. 6, no. 1, January 2008 (2008-01-01), XP008143124 *
See also references of EP2272519A4

Also Published As

Publication number Publication date
CN102056611A (zh) 2011-05-11
JP2011516606A (ja) 2011-05-26
US20110104289A1 (en) 2011-05-05
EP2272519A4 (en) 2011-04-27
BRPI0822165A2 (pt) 2015-06-16
IL208723A0 (en) 2010-12-30
CA2721509A1 (en) 2009-10-22
EP2272519A1 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
WO2009128692A1 (es) Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas
ES2641613T3 (es) Gel transdérmico de Nestorone®/Estradiol
ES2586122T3 (es) Formulaciones de testosterona
ES2204780T3 (es) Sistema terapeutico transdermico para la enfermedad de parkinson que induce altos niveles de rotigotina en plasma.
JP6353577B2 (ja) 組み合わせ組成物
WO2004105694A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CN102159196B (zh) 治疗上消化道用的药用制剂
ES2539582T3 (es) Soluciones de testosterona para el tratamiento del déficit de testosterona
BR112020002966A2 (pt) antagonistas de receptor de fator de liberação de corticotropina
PT2387389T (pt) Formulação para administração por via transmucosa bucal de moléculas antálgicas e/ou antiespasmódica
US20120040970A1 (en) Intranasal delivery system for dantrolene
Shahiwala et al. Nasal delivery of levonorgestrel for contraception: an experimental study in rats
US9408802B1 (en) Seven day drug in adhesive transdermal delivery
WO2019161470A1 (pt) Composição farmacêutica na forma de suspensão aquosa e uso de uma composição farmacêutica na forma de suspensão aquosa
CA3044091A1 (en) Tofacitinib and baclofen compositions and applications
CN102596194A (zh) 组合药物
WO2011064769A1 (en) Methods and pharmaceutical compositions for the treatment of hot flashes
Kakad et al. A recent review on nasal drug delivery system
CN104510725A (zh) 一种普拉克索周效透皮贴剂及其制备方法
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
Shaikh et al. A review on mucoadhesive drug delivery system
BE1018506A3 (nl) Samenstelling van een hydrocortisone, zijn derivaten, metabolieten, prodrugs of mengsels daarvan houdende liposomale gel en het gebruik ervan.
MX2010011296A (es) Metodo y composicion farmaceutica para lograr niveles plasmaticos de progesterona requeridos para diferentes indicaciones terapeuticas.
ES2336578T3 (es) Uso de pilocarpina para el tratamiento de hiposialismos.
US20120263784A1 (en) Emergency contraceptive

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880129432.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08741598

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011504940

Country of ref document: JP

Ref document number: D2010199

Country of ref document: CU

WWE Wipo information: entry into national phase

Ref document number: 2721509

Country of ref document: CA

Ref document number: 201011733

Country of ref document: CR

Ref document number: MX/A/2010/011296

Country of ref document: MX

Ref document number: CR2010-011733

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10130867

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2008741598

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 7704/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010144563

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12937779

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0822165

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101014